Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Abivax S.A.NASDAQ: ABVX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows 51.0% year over year
Q2 FY2026 research & development of €58.34M rose 51.0% year over year. Over 3 fiscal years it compounded at +54.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 177.76M EUR
- Year-over-year change
- +21.3%
- 4-year CAGR
- +38.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 177.76M | +21.3% |
| FY2024 | 2024-12-31 | 146.53M | +42.0% |
| FY2023 | 2023-12-31 | 103.18M | +113.6% |
| FY2022 | 2022-12-31 | 48.3M | +1.1% |
| FY2021 | 2021-12-31 | 47.78M | — |
Research & Development vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.3% is the 5th highest of 11, against a peer median of +13.9%.
- Over three fiscal years its annual growth of +54.4% compares with a peer median of +18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M USD | +2.5% | +22.0% | 424.8% | |
| LTM Aug 2026 | $331.95M USD | +10.2% | +18.6% | 47.3% | |
| LTM Sep 2026 | $259.72M USD | +46.3% | +43.1% | 287.0% | |
| LTM Mar 2026 | $255.99M USD | +3.7% | +29.7% | 117.9% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $55.01M USD | +74.4% | +17.0% | 93235.6% | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
| Peer median (excluding ABVX) | — | +13.9% | +18.3% | 355.9% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 45.52M | 50.76M | 0 | 0 | 0 |
| Gross Profit | (45.52M) | (50.76M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.78M | 48.3M | 103.18M | 146.53M | 177.76M |
| Selling, General & Admin | 5.58M | 7.49M | 28.82M | 38.9M | 72.87M |
| Operating Expenses | (4.12M) | 14.07M | 127.38M | 172.98M | 246.06M |
| Depreciation & Amortization | 302K | 485K | 707K | 1.1M | 1.07M |
| EBITDA | (38.59M) | (53.32M) | (133.21M) | (162.71M) | (300.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.4M) | (64.84M) | (127.38M) | (172.98M) | (246.06M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 2.77M | 8.96M | 5.75M |
| Interest Expense | 3.56M | 6.94M | 13.83M | 12.43M | 28.48M |
| Other Income / Expenses | (1.05M) | 4.1M | (20.36M) | (3.26M) | (84.2M) |
| Income Before Tax | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (330.25M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 5.85M |
| Net Income | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (336.1M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| EPS (Diluted) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| Weighted Avg Shares | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
| Weighted Avg Shares (Diluted) | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.